Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database
Abstract The combination of immune checkpoint inhibitors (ICIs), such as ipilimumab and nivolumab, has revolutionized cancer treatment, particularly for advanced melanoma and other solid tumors. However, rare adverse events (AEs) associated with this combination are often underreported in clinical t...
Saved in:
| Main Authors: | Xianyu Dai, Hongliang Cao, Jiajun Li, Tao Zhang, Yuchuan Hou |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-07287-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yutong Wu, et al.
Published: (2025-05-01) -
Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01) -
Disproportionality analysis and risk factor assessment of drug-associated thyroid dysfunction adverse events: a study based on the FAERS database
by: Zhifang Wang, et al.
Published: (2025-07-01) -
A disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS database
by: Feifei Wang, et al.
Published: (2025-07-01) -
Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
by: Shan Lin, et al.
Published: (2024-10-01)